The abstract is read at the publisher; the summary is JClub's.
Enzalutamide plus testosterone suppression improved overall survival versus a first-generation nonsteroidal antiandrogen in metastatic hormone-sensitive prostate cancer, with 8-year OS 50% vs 40% (HR 0.73).
- Why it matters: Longer follow-up is needed to confirm durability of survival benefit and to clarify adverse events and causes of death beyond earlier median follow-up reports.
- What they did: In a randomized 1:1 trial of 563 vs 562 participants with mHSPC receiving testosterone suppression plus enzalutamide or NSAA (early docetaxel allowed), investigators assessed OS, progression-free survival, cause-specific survival, treatment duration, and grade 3–5 AEs over a median 8.1-year follow-up.
- The result: Deaths were 285/563 vs 337/562, with fewer prostate-cancer deaths (207 vs 261) and similar other-cause deaths (78 vs 76); clinical PFS at 8 years was 43% vs 20%, and grade 3–5 cardiac and nervous system AE rates were similar, though falls were higher (0.70 vs 0.24).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.